{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:10:56Z","timestamp":1792829456802,"version":"4.5.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec id=\"ab-csc240004-1\"><jats:title>Importance<\/jats:title><jats:p>Limited availability and affordability of cancer drugs contribute to staggering disparities in cancer survival between high-income and low- and middle-income countries (LMICs). As infrastructure for cancer care rapidly develops, there is an urgent need to reduce prices and improve access to cancer medicines in LMICs to advance pharmacoequity globally.<\/jats:p><\/jats:sec><jats:sec id=\"ab-csc240004-2\"><jats:title>Observations<\/jats:title><jats:p>Prior strategies to expand access to cancer medicines in LMICs have primarily relied on charity or differential pricing and have yielded limited results. Policymakers at the World Health Assembly recently proposed several strategies to increase global access to cancer drugs. Reviewing empirical data and lessons learned from medication access programs for HIV, COVID-19, and other infectious diseases, 3 strategies that multilateral organizations can use to reduce prices of cancer drugs in LMICs are discussed herein. These include (1) building regional technology transfer and manufacturing hubs, (2) expanding and streamlining use of compulsory licenses, and (3) implementing global standards for drug price transparency. Counterpoints to the critiques of these policies are critiqued and how programs can use these strategies to build on existing disease-centered initiatives is discussed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-csc240004-3\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Lessons learned from the global response to HIV and COVID-19 show that international collaboration and support from the World Health and Trade Organizations can ensure a unified, coordinated agenda for advancing access to care in LMICs. Building on these lessons and implementing similar approaches for cancer drugs can play a critical role in expanding accessibility and affordability of cancer medicines in LMICs. With a growing burden of cancer morbidity and mortality in LMICs, redoubled efforts to deliver essential cancer medications to LMICs would have an immense impact on global cancer control and achieving the United Nations Sustainable Development Goals.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.5032","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T17:30:54Z","timestamp":1731605454000},"page":"55","source":"Crossref","is-referenced-by-count":12,"title":["Advancing Global Pharmacoequity in Oncology"],"prefix":"10.1001","volume":"11","author":[{"given":"Parsa","family":"Erfani","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth L.","family":"Okediji","sequence":"additional","affiliation":[{"name":"Harvard Law School, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Mulema","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative Inc, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics and Law, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwanele","family":"Asante-Shongwe","sequence":"additional","affiliation":[{"name":"South African Non-Communicable Diseases Alliance, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany L.","family":"Bychkovsky","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temidayo","family":"Fadelu","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"csc240004r3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(21)00575-1","article-title":"WHO Essential Medicines Committee spotlights unaffordable drugs.","volume":"22","author":"Furlow","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"csc240004r4","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S1470-2045(21)00706-3","article-title":"Essential medicines list in national cancer control plans: a secondary analysis from a global study.","volume":"23","author":"Razis","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"csc240004r5","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1093\/annonc\/mdx521","article-title":"ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"csc240004r6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.","volume":"22","author":"Fundytus","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"csc240004r7","doi-asserted-by":"publisher","first-page":"e1860","DOI":"10.1016\/S2214-109X(22)00376-X","article-title":"Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward.","volume":"10","author":"Jenei","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"6","key":"csc240004r8","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S1470-2045(21)00720-8","article-title":"Cancer in sub-Saharan Africa: a Lancet Oncology Commission.","volume":"23","author":"Ngwa","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10426","key":"csc240004r9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0140-6736(23)01913-X","article-title":"Health implications of GSK\u2019s departure from Nigeria.","volume":"403","author":"Aderinto","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"csc240004r12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.31768\/2312-8852.2017.39(2):151-154","article-title":"Generic imatinib in the treatment of chronic myeloid leukemia: two years\u2019 experience in Latvia.","volume":"39","author":"Lejniece","year":"2017","journal-title":"Exp Oncol"},{"key":"csc240004r13","doi-asserted-by":"publisher","first-page":"v13","DOI":"10.1093\/annonc\/mdt323","article-title":"Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.","volume":"24","author":"Lopes","year":"2013","journal-title":"Ann Oncol"},{"key":"csc240004r18","article-title":"Rethinking trade treaties and access to Medicines after COVID-19: a revised research agenda.","author":"Working Group on Trade and Investment Treaties and Access to Medicines","journal-title":"Glob Dev Policy Cent"},{"issue":"6","key":"csc240004r21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00304-7","article-title":"New coalition to increase access to cancer medicines in LMICs.","volume":"23","author":"Burki","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"csc240004r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36642\/mjil.43.1.fostering","article-title":"Fostering production of pharmaceutical products in developing countries.","volume":"43","author":"Fisher","year":"2022","journal-title":"Michigan J Int Law"},{"issue":"3","key":"csc240004r28","doi-asserted-by":"publisher","first-page":"e243474","DOI":"10.1001\/jamanetworkopen.2024.3474","article-title":"Estimated sustainable cost-based prices for diabetes medicines.","volume":"7","author":"Barber","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"csc240004r30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.7326\/M22-0756","article-title":"Potential Medicare Part D savings on generic drugs from the Mark Cuban Cost Plus Drug Co.","volume":"175","author":"Lalani","year":"2022","journal-title":"Ann Intern Med"},{"issue":"2","key":"csc240004r31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(15)70012-4","article-title":"Towards a global cancer fund.","volume":"16","author":"Cavalli","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"csc240004r32","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/bmjgh-2019-002061","article-title":"Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB.","volume":"5","author":"Chalkidou","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"4","key":"csc240004r33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1057\/s42214-020-00068-4","article-title":"Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? a review of the existing evidence.","volume":"3","author":"Urias","year":"2020","journal-title":"J Int Bus Policy"},{"issue":"5","key":"csc240004r34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/JGO.2016.005363","article-title":"Compulsory licenses for cancer drugs: does circumventing patent rights improve access to oncology medications?","volume":"2","author":"Bognar","year":"2016","journal-title":"J Glob Oncol"},{"key":"csc240004r38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6015","article-title":"Bayer challenges India\u2019s first compulsory licence for generic version of cancer drug.","volume":"345","author":"Arie","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"csc240004r42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jiel\/5.2.469","article-title":"The Doha Declaration on the TRIPS Agreement and public health: lighting a dark corner at the WTO.","volume":"6","author":"Abbott","year":"2002","journal-title":"Comput Law Secur Rev"},{"issue":"1","key":"csc240004r43","doi-asserted-by":"publisher","first-page":"e186875","DOI":"10.1001\/jamanetworkopen.2018.6875","article-title":"Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies.","volume":"2","author":"Tay-Teo","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"10","key":"csc240004r44","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1073\/pnas.1715368115","article-title":"Contribution of NIH funding to new drug approvals 2010-2016.","volume":"115","author":"Galkina Cleary","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"csc240004r45","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/s12885-017-3553-5","article-title":"Country and regional variations in purchase prices for essential cancer medications.","volume":"17","author":"Cuomo","year":"2017","journal-title":"BMC Cancer"},{"key":"csc240004r48","doi-asserted-by":"publisher","first-page":"l5375","DOI":"10.1136\/bmj.l5375","article-title":"Price transparency is a step towards sustainable access in middle income countries.","volume":"368","author":"Cernuschi","year":"2020","journal-title":"BMJ"},{"key":"csc240004r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2022.11.002","article-title":"Evidence on the effectiveness of policies promoting price transparency - A systematic review.","volume":"134","author":"Joosse","year":"2023","journal-title":"Health Policy"},{"key":"csc240004r1","unstructured":"Today? C. World Health Organization. Published 2022. Accessed April 8, 2024. https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/bars?mode=population&populations=987_988_989_990&group_populations=0&types=0_1&sort_by=value1&key=total&age_end=14"},{"key":"csc240004r2","unstructured":"Global Oncology Trends 2022 - IQVIA. Accessed July 30, 2022. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/global-oncology-trends-2022"},{"key":"csc240004r10","unstructured":"World Health Organization. The Selection and Use of Essential Medicines. WHO Tech Rep Ser. Published online January 27, 2022:1-881. Accessed March 17, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240041134"},{"key":"csc240004r11","unstructured":"? WHO. Technical Report: Pricing of Cancer Medicines and Its Impacts: A Comprehensive Technical Report for the World Health Assembly Resolution 70.12.; 2018. Accessed March 17, 2024. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/277190\/9789241515115-eng.pdf?ua=1"},{"key":"csc240004r14","unstructured":"The path that ends AIDS: UNAIDS Global AIDS Update 2023. Jt United Nations Progr HIV\/AIDS. Published online 2039. Accessed April 8, 2024. https:\/\/www.wipo.int\/amc\/en\/mediation\/rules"},{"key":"csc240004r15","unstructured":"Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020. World Heal Organ. Published online 2021. Accessed March 17, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240019003"},{"key":"csc240004r16","unstructured":"The mRNA vaccine technology transfer hub. Accessed July 31, 2022. https:\/\/www.who.int\/initiatives\/the-mrna-vaccine-technology-transfer-hub"},{"key":"csc240004r17","unstructured":"Recipients of mRNA technology from the WHO mRNA technology transfer hub. Accessed March 17, 2024. https:\/\/www.who.int\/initiatives\/the-mrna-vaccine-technology-transfer-hub\/recipients-of-mrna-technology-from-the-who-mrna-technology-transfer-hub"},{"key":"csc240004r19","unstructured":"License? N. Medicines Patent Pool. Published 2022. Accessed March 17, 2024. https:\/\/medicinespatentpool.org\/licence-post\/nilotinib"},{"key":"csc240004r20","unstructured":"WHO and St. Jude to dramatically increase global access to childhood cancer medicines. World Health Organization. Published December 13, 2021. Accessed April 8, 2024. https:\/\/www.who.int\/news\/item\/13-12-2021-who-and-st.-jude-to-dramatically-increase-global-access-to-childhood-cancer-medicines"},{"key":"csc240004r22","unstructured":"Agreement on Trade-Related Aspects of Intellectual Property Rights. World Trade Organization. Published April 15, 1994. Accessed May 1, 2024. https:\/\/www.wto.org\/english\/docs_e\/legal_e\/27-trips_01_e.htm"},{"key":"csc240004r23","unstructured":"Academy? WHO. World Health Organization. Accessed March 17, 2024. https:\/\/www.who.int\/about\/who-academy"},{"key":"csc240004r25","unstructured":"Global Benchmarking Tools. World Health Organization. Accessed March 18, 2024. https:\/\/www.who.int\/tools\/global-benchmarking-tools"},{"key":"csc240004r26","unstructured":"Prequalification of medicines by WHO. World Health Organization. Accessed March 18, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/prequalification-of-medicines-by-who#"},{"key":"csc240004r27","unstructured":"\u2019t Hoen? E. Fair Medicines Pricing requires addressing monopolies and increasing transparency in pharmaceutical markets. Medicines Law & Policy. Published February 8, 2024. Accessed March 17, 2024. https:\/\/medicineslawandpolicy.org\/2024\/02\/fair-medicines-pricing-requires-addressing-monopolies-and-increasing-transparency-in-pharmaceutical-markets\/"},{"key":"csc240004r29","unstructured":"Struver? Z. Biolyse Pharma offers to supply enzalutamide (Xtandi) for $3 per pill to Medicare and developing countries. Knowledge Ecology International. Published April 28, 2016. Accessed April 17, 2024. https:\/\/www.keionline.org\/23069"},{"key":"csc240004r35","unstructured":"Silverman? E. Colombia moves to issue a compulsory license for an HIV medicine. STAT News. Accessed March 18, 2024. https:\/\/www.statnews.com\/pharmalot\/2024\/02\/06\/gsk-viiv-hiv-colombia-aids-patent-medicines\/"},{"key":"csc240004r36","unstructured":"Compulsory License and. \u201cGovernment Use\u201d to Promote Access to Medicines: Some Examples.; 2014. Accessed August 1, 2022. https:\/\/www.twn.my\/title2\/books\/CompulsoryLicense.htm"},{"key":"csc240004r37","unstructured":"Access to Cancer Treatment. A study of medicine pricing issues with recommendations for improving access to cancer medication. Oxfam Policy & Practice. Published February 4, 2015. Accessed August 1, 2022. https:\/\/policy-practice.oxfam.org\/resources\/access-to-cancer-treatment-a-study-of-medicine-pricing-issues-with-recommendati-344070\/"},{"key":"csc240004r39","unstructured":"Dangi-Garimella? S. Colombia Takes a Stand on Price of Novartis\u2019 Leukemia Drug. The American Journal of Managed Care. Published September 20, 2016. Accessed May 1, 2024. https:\/\/www.ajmc.com\/view\/colombia-takes-a-stand-on-price-of-novartis-leukemia-drug"},{"key":"csc240004r40","unstructured":"Compulsory licensing of pharmaceuticals and TRIPS. World Trade Organization. Accessed August 1, 2022. https:\/\/www.wto.org\/english\/tratop_e\/trips_e\/public_health_faq_e.htm"},{"key":"csc240004r41","unstructured":"Declaration on the TRIPS agreement and public health. World Trade Organization - Doha 4th Ministerial. Published November 14, 2001. Accessed May 1, 2024. https:\/\/www.wto.org\/english\/thewto_e\/minist_e\/min01_e\/mindecl_trips_e.htm"},{"key":"csc240004r46","unstructured":"Improving the transparency of markets for medicines, vaccines, and other health products. Seventy-Second World Heal Assem. Published online May 18, 2019. Accessed March 17, 2024. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA72\/A72_R8-en.pdf"},{"key":"csc240004r47","unstructured":"Katrina? P. Mara Kaitlin &, \u2019t Hoen E. What is the evidence on legal measures to improve the transparency of markets for medicines, vaccines and other health products (?World Health Assembly resolution WHA72.8)?? World Health Organization. Published 2021. Accessed March 18, 2024. https:\/\/iris.who.int\/handle\/10665\/342474"},{"key":"csc240004r49","unstructured":"Barrenhoi? E, Loperti? R. Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets | OECD Health Working Papers. OECD iLibrary. Published September 8, 2022. Accessed March 18, 2024. https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/exploring-the-consequences-of-greater-price-transparency-on-the-dynamics-of-pharmaceutical-markets_c9250e17-en"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2826180\/jamaoncology_erfani_2024_sc_240004_1743446606.87752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T20:09:08Z","timestamp":1743797348000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2826180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.5032","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}